Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 116, Issue 8, Pages 2115-2121Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI28968
Keywords
-
Categories
Funding
- NHLBI NIH HHS [R01 HL076839, HL76839] Funding Source: Medline
- NIAMS NIH HHS [R01 AR050200, AR050200] Funding Source: Medline
Ask authors/readers for more resources
Hutchinson-Gilford progeria syndrome (HGPS) is caused by the production of a truncated prelamin A, called progerin, which is farnesylated at its carboxyl terminus. Progerin is targeted to the nuclear envelope and causes misshapen nuclei. Protein farnesyltransferase inhibitors (FTI) mislocalize progerin away from the nuclear envelope and reduce the frequency of misshapen nuclei. To determine whether an FTI would ameliorate disease phenotypes in vivo, we created gene-targeted mice with an HGPS mutation (Lmna(HG/+)) and then examined the effect of an FTI on disease phenotypes. Lmna(HG/+) mice exhibited phenotypes similar to those in human HGPS patients, including retarded growth, reduced amounts of adipose tissue, micrognathia, osteoporosis, and osteolytic lesions in bone. Osteolytic lesions in the ribs led to spontaneous bone fractures. Treatment with an FTI increased adipose tissue mass, improved body weight curves, reduced the number of rib fractures' and improved bone mineralization and bone cortical thickness. These studies suggest that FTIs could be useful for treating humans with HGPS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available